Profile
Heiko von der Leyen is currently the Medical Director at Orgenesis, Inc. He previously worked as the Managing Director at Hannover Clinical Trial Center GmbH from 2005 to 2017.
Prior to that, he was the Medical Director & VP-Clinical Development at Cardion GmbH from 1998 to 2001.
He also served as the Chief Scientific Officer at Avontec GmbH in 2003 and at Artiss GmbH in 2001-2002.
Heiko von der Leyen active positions
| Companies | Position | Start |
|---|---|---|
| ORGENESIS INC. | Chief Tech/Sci/R&D Officer | 01/09/2020 |
Former positions of Heiko von der Leyen
| Companies | Position | End |
|---|---|---|
| Hannover Clinical Trial Center GmbH | Corporate Officer/Principal | 01/01/2017 |
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Chief Tech/Sci/R&D Officer | 01/01/2004 |
| Artiss GmbH | Chief Tech/Sci/R&D Officer | 01/01/2002 |
Cardion GmbH
 Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Chief Tech/Sci/R&D Officer | 01/01/2001 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ORGENESIS INC. | Health Technology |
| Private companies | 4 |
|---|---|
Cardion GmbH
Cardion GmbH Medical SpecialtiesHealth Technology Cardion GmbH develops biopharmaceutical products. It integrates synergistic local gene delivery stem cell engineering and tolerance induction capabilities to build cardiovascular gene therapy products. The company is headquartered in Dusseldorf, Germany. | Health Technology |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
| Hannover Clinical Trial Center GmbH | |
| Artiss GmbH |
- Stock Market
- Insiders
- Heiko von der Leyen
